Free Trial
NYSE:MBX

MBX Biosciences 11/7/2024 Earnings Report

MBX Biosciences logo
$14.84 +0.58 (+4.03%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MBX Biosciences EPS Results

Actual EPS
-$2.78
Consensus EPS
-$2.72
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

MBX Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MBX Biosciences Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

MBX Biosciences Earnings Headlines

MBX Biosciences (MBX) versus The Competition Head-To-Head Survey
This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
MBX Biosciences Submits IND for Once-Monthly Obesity Drug
Reviewing MBX Biosciences (MBX) & Its Rivals
A Glimpse of MBX Biosciences's Earnings Potential
See More MBX Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MBX Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MBX Biosciences and other key companies, straight to your email.

About MBX Biosciences

MBX Biosciences (NYSE:MBX), a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

View MBX Biosciences Profile

More Earnings Resources from MarketBeat